What's Happening?
Genentech, a member of the Roche Group, has announced positive results from its Phase III Krascendo 1 study, which evaluated divarasib, an investigational next-generation KRAS G12C inhibitor. The study compared divarasib against first-generation KRAS G12C inhibitors,
sotorasib and adagrasib, in patients with previously treated KRAS G12C non-small cell lung cancer (NSCLC). The trial met its primary and key secondary endpoints, showing clinically meaningful and statistically significant improvements in progression-free survival (PFS) and overall survival (OS). The safety profile of divarasib was consistent with previous data, with no new safety signals observed. The study's results suggest that divarasib could become a new standard of care for patients with this specific genetic mutation in NSCLC.
Why It's Important?
The results of the Krascendo 1 study are significant as they address a critical unmet need in lung cancer treatment. KRAS G12C mutations are found in approximately 14% of NSCLC cases and are associated with poor prognosis. The superior efficacy of divarasib in improving survival outcomes could offer a new therapeutic option for patients with this mutation, potentially improving their quality of life and survival rates. The study's findings also reinforce the importance of precision medicine in oncology, as targeted therapies like divarasib can provide more effective treatment options for genetically defined tumor subtypes.
What's Next?
Genentech plans to present the data from the Krascendo 1 study at an upcoming medical meeting and submit it to health authorities. The goal is to make divarasib available to patients with KRAS G12C NSCLC as soon as possible. The U.S. Food and Drug Administration has already granted Breakthrough Therapy Designation to divarasib, highlighting its potential impact on lung cancer treatment. As Genentech continues its comprehensive Phase III clinical development program, further studies will explore divarasib as both a monotherapy and in combination with other treatments across different disease settings.
